Compounds > mk 767
Page last updated: 2024-09-04

mk 767 and duloxetine

mk 767 has been researched along with duloxetine in 1 studies

Compound Research Comparison

Studies
(mk 767)		Trials
(mk 767)		Recent Studies (post-2010)
(mk 767)		Studies
(duloxetine)		Trials
(duloxetine)		Recent Studies (post-2010) (duloxetine)
3201051023

Protein Interaction Comparison

ProteinTaxonomymk 767 (IC50)duloxetine (IC50)
Gamma-aminobutyric acid receptor subunit piHomo sapiens (human)0.019
Gamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)0.019
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)2.8
Cytochrome P450 1A2Homo sapiens (human)5.3
Cytochrome P450 3A4Homo sapiens (human)0.44
Cytochrome P450 2D6Homo sapiens (human)1.5438
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)0.019
Potassium voltage-gated channel subfamily E member 1Homo sapiens (human)10
Gamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)0.019
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)0.019
Sodium-dependent noradrenaline transporter Homo sapiens (human)0.0886
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)0.37
Gamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)0.019
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)0.019
Sodium-dependent serotonin transporterHomo sapiens (human)0.0052
Cytochrome P450 2C19Homo sapiens (human)4.1
Serine hydroxymethyltransferase, mitochondrialHomo sapiens (human)6.9183
Gamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)0.019
Gamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)0.019
Gamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)0.019
Gamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)0.019
Potassium voltage-gated channel subfamily KQT member 1Homo sapiens (human)10
Gamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)0.019
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)2.8
Sodium-dependent dopamine transporter Homo sapiens (human)0.8093
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)7.1071
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)2.8
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)2.8
Sodium channel protein type 5 subunit alphaHomo sapiens (human)7.9433
Gamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)0.019
Beta-2 adrenergic receptorCavia porcellus (domestic guinea pig)0.003
Gamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)0.019
Gamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)0.019
Gamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)0.019

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Morphy, R; Rankovic, Z1

Reviews

1 review(s) available for mk 767 and duloxetine

ArticleYear
Designed multiple ligands. An emerging drug discovery paradigm.
    Journal of medicinal chemistry, 2005, Oct-20, Volume: 48, Issue:21

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors

2005